QT Imaging's Quantitative Ultrasound Technology and Science to be Front and Center at RSNA 2025
MWN-AI** Summary
QT Imaging Holdings, Inc. is set to showcase its innovative Quantitative Ultrasound Technology at the upcoming RSNA 2025, held from November 30 to December 4 in Chicago, IL. Dr. Elaine Luanow, the company's Chief Medical Officer, will present a seminar titled “Quantitative Transmission Imaging Technology: The Future of Breast Imaging with Safe Volumetric Ultrasound” on December 3. The seminar aims to highlight advancements in image quality and the company's evolution from a hardware-centric startup to a biomarker-driven AI imaging enterprise.
Attendees at RSNA 2025 are invited to experience live demonstrations of the FDA-cleared QTI Breast Acoustic CT™, the first non-invasive breast imaging technology that captures true 3D images of breast anatomy without the need for compression, contrast agents, or harmful radiation. This technology signifies a substantial shift in how breast health can be managed, offering patients a safer and more comfortable imaging alternative.
QT Imaging focuses on utilizing low-frequency sound waves for body imaging, emphasizing the importance of safety, accessibility, and patient-centered experiences in medical imaging. The company's commitment to enhancing global health outcomes is reflected in its strategic approach, which prioritizes the development and commercialization of advanced imaging systems.
The announcements coincide with QT Imaging's ambitions to expand its product offerings and capitalize on its transformative journey, addressing the significant needs within breast health management. As the medical community converges at RSNA 2025, QT Imaging aims to position its cutting-edge technology at the forefront of breast imaging conversations, paving the way for future advancements in the field. For more information, visit QT Imaging’s website at www.qtimaging.com.
MWN-AI** Analysis
QT Imaging Holdings, Inc. (OTCQB: QTIH) is poised to make a significant impact at RSNA 2025 with its groundbreaking Quantitative Transmission Imaging Technology, especially in the realm of breast health management. As the company transitions from a hardware-centric model to a biomarker-driven AI imaging approach, their presence at the event, specifically through the seminar led by Chief Medical Officer Dr. Elaine Luanow, promises to showcase the innovative edge QT Imaging holds in the medical imaging landscape.
QT Imaging’s flagship product, the QTI Breast Acoustic CT™ scanner, represents a paradigm shift in breast imaging. With its FDA clearance, the scanner offers non-invasive, true 3D imaging without the drawbacks of conventional methods—namely, the use of ionizing radiation and the discomfort associated with compression. This technology's emphasis on patient safety and accessibility places QT Imaging in alignment with the growing demand for less invasive medical alternatives.
Investors should regard this innovation not just as a product, but as part of a broader market trend favoring AI-enabled diagnostics and imaging. The company's seminar and live demonstrations will likely attract attention from healthcare professionals and industry stakeholders, enhancing its visibility and potentially driving future partnerships or sales.
As QT Imaging continues to highlight advancements in imaging quality and AI integration, its stock may experience upward momentum, particularly if successful adoption rates and clinical outcomes are demonstrated post-event. However, it is important to remain mindful of the inherent risks associated with product commercialization and market fluctuations outlined in their filings.
In summary, the upcoming RSNA 2025 serves as a pivotal platform for QT Imaging to solidify its position and drive growth within the medical device sector, making it a compelling watch for investors interested in healthcare innovation.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Company seminar and technology demos to be hosted by its strategic partner, Canon Medical Systems USA
QT Imaging Holdings, Inc. (“QT Imaging” or the “Company”) (OTCQB: QTIH), a medical device company dedicated to transforming breast health management through innovative, radiation-free imaging technology, is pleased to announce that its Chief Medical Officer, Elaine luanow, MD, will host a seminar titled “Quantitative Transmission Imaging Technology: The Future of Breast Imaging with Safe Volumetric Ultrasound” at the upcoming 111th Scientific Assembly and Annual Meeting of the Radiological Society of North America (“RSNA 2025”) being held in Chicago, IL, November 30 – December 4, 2025.
Dr. luanow’s RSNA 2025 seminar, which will be delivered in-person at 1:00pm CT on Dec 3 rd at the Canon Workshop (Booth #8349, North Hall), will show technology advancements in image quality as well as the drivers behind QT Imaging’s major transformation from a hardware-focused startup to a biomarker-driven AI imaging company.
QTI Imaging is also pleased to invite RSNA 2025 attendees to visit Booth #6713, in the North Hall, for live demonstrations of its FDA-cleared QTI Breast Acoustic CT™ scanner - the first non-invasive breast imaging technology that provides a true 3D image of the breast anatomy without compression, contrast administration, or harmful ionizing radiation.
About QT Imaging Holdings, Inc.
QT Imaging Holdings, Inc. is a public (OTCQB: QTIH) medical device company engaged in research, development, and commercialization of innovative body imaging systems using low frequency sound waves. QT Imaging Holdings, Inc. strives to improve global health outcomes. Its strategy is predicated upon the fact that medical imaging is critical to the detection, diagnosis, and treatment of disease and that it should be safe, affordable, accessible, and centered on the patient’s experience. For more information on QT Imaging Holdings, Inc., please visit the company’s website at www.qtimaging.com .
Breast Acoustic CT™ is a trademark of an affiliate of QT Imaging Holdings, Inc.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements contain words such as “will,” and “expect,” or the negative thereof or comparable terminology, and include (without limitation) statements regarding QT Imaging Breast Acoustic CT imaging technology, plans for QT Imaging Holdings, including its transformation from a hardware-focused startup to a biomarker-driven AI imaging company, new product development and introduction, and product sales growth and projected revenues. Forward-looking statements involve certain risks and uncertainties, and actual results may differ materially from those discussed in any such statement. These risks include, but are not limited to: research results from the use of the QT Imaging Breast Acoustic CT Scanner, the ability of QT Imaging Holdings to sell and deploy the QT Imaging Breast Acoustic CT Scanner, the ability to extend product offerings into new areas or products, the ability to commercialize technology, unexpected occurrences that deter the full documentation and “bring to market” plan for products, trends, and fluctuations in the industry, changes in demand and purchasing volume of customers, unpredictability of suppliers, the ability to attract and retain qualified personnel, and the ability to move product sales to production levels. Additional factors that could cause actual results to differ are discussed under the heading “Risk Factors” and in other sections of QT Imaging Holdings’ filings with the SEC, and in its other current and periodic reports filed or furnished from time to time with the SEC. All forward-looking statements in this press release are made as of the date hereof, based on information available to QT Imaging Holdings as of the date hereof, and QT Imaging Holdings assumes no obligation to update any forward-looking statement.
View source version on businesswire.com: https://www.businesswire.com/news/home/20251103279727/en/
For media inquiries, please contact:
Stephen Kilmer
Head of Investor Relations
Stephen.Kilmer@qtimaging.com
Direct: (646) 274-3580
FAQ**
How does QT Imaging Holdings, Inc. (QTIH) plan to highlight its transition to a biomarker-driven AI imaging company during the RSNA 2025 seminar?
What feedback has QT Imaging received regarding the live demonstrations of its FDA-cleared Breast Acoustic CT™ scanner at the RSNA 20event?
Could QT Imaging Holdings (QTIH) elaborate on the expected outcomes or innovations discussed by Dr. Elaine Luanow regarding quantitative transmission imaging technology?
What strategies is QT Imaging Holdings (QTIH) implementing to mitigate the risks associated with commercializing its Breast Acoustic CT™ technology?
**MWN-AI FAQ is based on asking OpenAI questions about QT Imaging Holdi (OTC: QTIH).
NASDAQ: QTIH
QTIH Trading
-3.39% G/L:
$5.70 Last:
887 Volume:
$6 Open:
